Shares of Intravenous Infusions Limited surged as much as 37.5% over five trading sessions on the Ghana Stock Exchange after CCM Healthcare Investments FZCO disclosed it had acquired over 1 million shares, sparking the most sustained rally the small-cap pharmaceutical stock has seen this year. The stock climbed from GHS 0.24 on July 8 to GHS 0.33 by July 14 — but with the price now flat at yesterday's close, investors face the central question: is this a turning point backed by real strategic capital, or a brief sugar rush on thin volume? CCM Healthcare's Million-Share Bet Lifts Intravenous Infusions — But Can a Turnaround Story Survive Going-Concern Doubts?
Shares of Ghana's oldest IV-fluid maker rocketed 37.5% in five sessions after CCM Healthcare Investments FZCO disclosed a purchase of over one million shares on July 9. The rally — from GHS 0.24 to GHS 0.33 — is the latest chapter in a remarkable 560% year-to-date surge for a company whose auditors recently questioned whether it can stay in business.
A Familiar Backer Doubles Down, Not a New Rescue CCM Healthcare is no stranger here. The Dubai-registered firm previously extended a GH¢4.8 million convertible loan to the company , and shareholders approved converting that debt into equity at an extraordinary general meeting in February 2026 . The fresh share purchase signals CCM is choosing to increase its exposure rather than simply protect an existing loan — a meaningful vote of confidence. But investors should note this is a deepening bet by an existing creditor, not fresh institutional discovery.
The Financials Tell a Brutal Story Behind the stock chart euphoria sits a company in crisis. IIL recorded a net loss of GH¢4.63 million for 2025 as revenue collapsed 63% to GH¢9.3 million , driven by working capital pressures that crippled its ability to import raw materials . Independent auditors flagged "significant doubt" about the company's ability to continue as a going concern — essentially warning shareholders the business might not survive without fresh capital.
The GH¢50 Million Lifeline Is the Real Pivot The share purchase matters less than whether IIL can close its planned GH¢50 million capital raise — a rights issue (where existing shareholders buy new shares at a discount) backed by a private placement. That raise was expected to be completed by June 2026, with proceeds earmarked for working capital, debt servicing, and capacity improvements . Whether it closed on time is unclear; if it fell short, CCM's open-market buying may be filling the gap.
A Dominant Market Position in a Tiny, Illiquid Stock
IIL commands roughly 50% of Ghana's IV-fluids market and supplies hospitals, the armed forces, and police — an essential healthcare franchise. Yet its market capitalization is only about GHS 90.6 million , and the stock was inactive on 58% of recent trading days . In a stock this thinly traded, even modest buying can produce outsized price moves, meaning the rally may overstate the magnitude of CCM's commitment. Shareholders should watch for the capital-raise outcome and any production recovery — not the ticker — to judge whether this turnaround is real.